GlassScriptPhysician profile
Liliane Min
NPI 1366499758
$7,370.42
in general payments reported to CMS, 2019-2025
45 companies · $670 in 2025
The $670 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $1,023 · 2021: $690 · 2022: $1,044 · 2023: $1,503 · 2024: $727 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,664.00 | 2019-2025 | Evenity, Enbrel, Prolia |
| Abbvie INC. | $655.63 | 2019-2025 | |
| Ucb, INC. | $634.85 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $479.21 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $404.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $394.94 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $347.45 | 2019-2024 | Orencia |
| Radius Health, INC. | $262.18 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $212.83 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $200.37 | 2019-2025 | Taltz |
| Ani Pharmaceuticals, INC. | $176.82 | 2022-2023 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $149.06 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.23 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.07 | 2019-2023 | Cyltezo |
| Horizon Therapeutics Plc | $105.01 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liliane Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.